



28 April 2025

Tender results

In April 2025, Pharmac has not resolved to award any tenders for Principal Supply Status for products included in the 2024/25 Invitation to Tender dated 31 October 2024.

We are currently working to improve our decision making through further consultation for tender decisions. As part of this, there have been some changes to our usual timeframes. We are still working through evaluation of items included in the 2023/24 and 2024/25 Invitation to Tender and expect to announce these decisions over the coming months. We appreciate your patience and understanding while we improve our processes.

Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2022/23 Invitation to Tender, dated 31 October 2022.

Chemical Name	Line Item
Moxifloxacin	Tab 400 mg

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.

Chemical Name	Line Item
Ertapenem	Inj 1 g
Netupitant with palonosetron	Cap netupitant 300 mg with palonosetron 500 mcg

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2024/25 Invitation to Tender, dated 31 October 2024.

Chemical Name	Line Item
Fingolimod	Cap 0.5 mg
Multivitamins	Tab (BPC cap strength)
Nortriptyline hydrochloride	Tab 10 mg
Nortriptyline hydrochloride	Tab 25 mg
Omeprazole	Inj 40 mg ampoule with diluent
Omeprazole	Inj 40 mg
Pancreatic enzyme	Cap 150 mg
Pancreatic enzyme	Cap 175 mg
Pancreatic enzyme	Cap 300 mg
Pancreatic enzyme	Cap 420 mg

Progesterone	Cap 100 mg
Progesterone	Cap 200 mg
Methylphenidate hydrochloride (widened access)	Cap modified release 60 mg
Methylphenidate hydrochloride (current access)	Cap modified release 60 mg

For products included in the 2023/24 and 2024/25 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.